PTC Therapeutics, Inc. (NASDAQ:PTCT) has been given a consensus recommendation of “Hold” by the twelve brokerages that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $18.25.

PTCT has been the subject of several analyst reports. Citigroup reiterated a “buy” rating and issued a $28.00 target price on shares of PTC Therapeutics in a research note on Wednesday, September 27th. Zacks Investment Research upgraded shares of PTC Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Thursday. Barclays reduced their price objective on shares of PTC Therapeutics from $22.00 to $15.00 and set an “equal weight” rating for the company in a research report on Friday, September 29th. Cowen restated a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, October 25th. Finally, Royal Bank of Canada set a $15.00 price objective on shares of PTC Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, October 25th.

A number of large investors have recently bought and sold shares of PTCT. Point72 Asset Management L.P. raised its position in PTC Therapeutics by 1,587.8% during the third quarter. Point72 Asset Management L.P. now owns 400,000 shares of the biopharmaceutical company’s stock worth $8,004,000 after acquiring an additional 376,300 shares during the period. Vanguard Group Inc. grew its holdings in shares of PTC Therapeutics by 17.2% during the second quarter. Vanguard Group Inc. now owns 2,366,564 shares of the biopharmaceutical company’s stock worth $43,379,000 after buying an additional 346,525 shares in the last quarter. American Century Companies Inc. purchased a new stake in shares of PTC Therapeutics during the third quarter worth $3,936,000. RTW Investments LP grew its holdings in shares of PTC Therapeutics by 5.8% during the third quarter. RTW Investments LP now owns 3,495,143 shares of the biopharmaceutical company’s stock worth $69,938,000 after buying an additional 190,929 shares in the last quarter. Finally, AXA grew its holdings in shares of PTC Therapeutics by 1,439.0% during the second quarter. AXA now owns 161,600 shares of the biopharmaceutical company’s stock worth $2,962,000 after buying an additional 151,100 shares in the last quarter. Institutional investors own 86.12% of the company’s stock.

PTC Therapeutics (PTCT) traded down $0.06 on Friday, hitting $17.93. 555,732 shares of the company traded hands, compared to its average volume of 687,800. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.97 and a current ratio of 3.08. PTC Therapeutics has a 1 year low of $8.12 and a 1 year high of $22.00. The firm has a market cap of $743.91, a PE ratio of -6.20 and a beta of 1.23.

COPYRIGHT VIOLATION NOTICE: “PTC Therapeutics, Inc. (PTCT) Given Average Recommendation of “Hold” by Brokerages” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/05/ptc-therapeutics-inc-ptct-given-average-recommendation-of-hold-by-brokerages.html.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Analyst Recommendations for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.